共 50 条
Modulation of vasoconstrictor and dilator pancreatic metabolites in streptozotocine diabetic rats:: effect of bradykinin blockage and NO inhibition
被引:3
|作者:
Ortiz, MA
Roselló, J
Xaus, C
Peralta, C
Mato, E
Pou, JM
机构:
[1] Hosp Santa Creu & St Pau, Dept Endocrinol, Barcelona 08025, Spain
[2] Inst Invest Biomed, Dept Bionalit Med, Barcelona, Spain
来源:
PROSTAGLANDINS & OTHER LIPID MEDIATORS
|
1999年
/
57卷
/
5-6期
关键词:
nitric oxide;
diabetes;
streptozotocine;
bradykinin;
vasoconstriction;
vasodilation;
pancreas;
D O I:
10.1016/S0090-6980(98)00069-0
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
This study was designed to investigate the effect of HOE 140 (a bradykinin beta(2) receptor antagonist) and N-W-nitro-L-arginine methyl-ester (L-NAME, a nitric oxide synthase inhibitor) on endothelial and P-tell function in induced streptozotocine (Stz) diabetic rats. The decrease in the insulinogenic index after Stz effect (control 286.03 +/- 104.12 and Stz 18.22 +/- 10.77*, *P < 0.001 vs. Control) was partially prevented by L-NAME (46.54 +/- 10.12, P < 0.001) and HOE 140 (105.12 +/- 23.06, P < 0.001). It was observed in diabetic rats: L-NAME increased the pancreatic endothelin-1 (ET-1) production and HOE 140 did not. L-NAME and HOE 140 decreased the nitric oxide (NO) synthesis, increased prostacyclin 1-2 (PGI(2)), and did not modify thromboxane A-2 (TxA(2)). These results indicate that L-NAME and HOE 140 had a protective effect on the development of diabetes in the rat. The protective effect of L-NAME and HOE 140 on the insulinogenic index could be related to ET-1, bradykinin, PGI(2), and NO. (C) 1999 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:281 / 290
页数:10
相关论文